losartan has been researched along with Liver Neoplasms in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although viral hepatocellular carcinoma (HCC) is declining, nonviral HCC, which often is the end stage of nonalcoholic or alcoholic steatohepatitis (NASH, ASH), is on an upward trajectory." | 1.91 | Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. ( Chamseddine, S; Gu, L; Huang, JY; Karin, M; Kaseb, AO; Lee, M; Mohamed, YI; Nguyen, A; Pandit, SK; Ryujin, NT; Shalapour, S; Xiao, L; Zhu, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, L | 1 |
| Zhu, Y | 1 |
| Lee, M | 1 |
| Nguyen, A | 1 |
| Ryujin, NT | 1 |
| Huang, JY | 1 |
| Pandit, SK | 1 |
| Chamseddine, S | 1 |
| Xiao, L | 1 |
| Mohamed, YI | 1 |
| Kaseb, AO | 1 |
| Karin, M | 1 |
| Shalapour, S | 1 |
| Shen, Y | 1 |
| Wang, X | 1 |
| Lu, J | 1 |
| Salfenmoser, M | 1 |
| Wirsik, NM | 1 |
| Schleussner, N | 1 |
| Imle, A | 1 |
| Freire Valls, A | 1 |
| Radhakrishnan, P | 1 |
| Liang, J | 1 |
| Wang, G | 1 |
| Muley, T | 1 |
| Schneider, M | 1 |
| Ruiz de Almodovar, C | 1 |
| Diz-Muñoz, A | 1 |
| Schmidt, T | 1 |
| Takagi, H | 1 |
| Kaji, K | 1 |
| Nishimura, N | 1 |
| Ishida, K | 1 |
| Ogawa, H | 1 |
| Takaya, H | 1 |
| Kawaratani, H | 1 |
| Moriya, K | 1 |
| Namisaki, T | 1 |
| Akahane, T | 1 |
| Mitoro, A | 1 |
| Yoshiji, H | 1 |
3 other studies available for losartan and Liver Neoplasms
| Article | Year |
|---|---|
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells.
Topics: Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Humans; Liver Cirrhosis; Liver Neoplasms; Los | 2023 |
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2020 |
The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cytostatic Agents; Humans; Liver Neoplasms; Losart | 2021 |